Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
BioInvent International AB ( (SE:BINV) ) has issued an update.
BioInvent International AB has sold its future royalty and milestone rights for the cancer drug mezagitamab to XOMA Royalty for up to USD 30 million. This transaction provides BioInvent with non-dilutive capital to advance its drug development programs and reflects XOMA’s increased interest in mezagitamab, enhancing its royalty portfolio with potential future earnings from the drug’s commercial success.
More about BioInvent International AB
BioInvent International AB is a clinical-stage biotech company focused on discovering and developing novel antibodies for cancer immunotherapy. The company uses its proprietary technology platform to identify targets and antibodies, generating promising candidates for its clinical development pipeline and offering licensing opportunities.
Average Trading Volume: 101,277
Current Market Cap: SEK2.05B
For a thorough assessment of BINV stock, go to TipRanks’ Stock Analysis page.